Howard Wessel
About Howard Wessel
Howard Wessel serves as the Director of Research and Development at Noveome Biotherapeutics, Inc., where he leads a team focused on advancing the drug candidate ST266. He holds a B.S. in Life Science/Microbiology from Penn State University and an MBA in Health Sciences from Chatham University.
Work at Noveome Biotherapeutics
Howard Wessel serves as the Director of Research and Development at Noveome Biotherapeutics, Inc. since 2017. In this role, he manages a team of scientists focused on advancing the primary drug candidate ST266 towards market readiness. His leadership is integral to the research initiatives at the company, which is located in the Greater Pittsburgh Area.
Education and Expertise
Howard Wessel earned a Bachelor of Science degree in Life Science/Microbiology from Penn State University, where he studied from 1988 to 1993. He later obtained an MBA in Health Sciences from Chatham University, completing his studies between 2005 and 2007. His educational background supports his expertise in research and development in the biotherapeutics field.
Background
Prior to his current position, Howard Wessel worked as a consultant for Generin Diagnostics and Genzyme Corporation. His work involved developing enzyme assays for lysosomal storage disorders, contributing to advancements in diagnostic methodologies. He also specialized in corneal wound healing early in his career at the University of Pittsburgh's Department of Ophthalmology.
Publications and Research Contributions
Howard Wessel has co-authored several publications focused on corneal differentiation, neural protection, and surrogate markers for Gaucher disease. His research contributions reflect his commitment to advancing knowledge in the fields of ophthalmology and biotherapeutics.